Harvard Bioscience, Inc. (HBIO)
USD 2.03
(-6.45%)
USD 2.03
(-6.45%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 1.89 Million USD | 131.89% |
| 2022 | -7.16 Million USD | -611.86% |
| 2021 | 1.4 Million USD | 339.32% |
| 2020 | -585 Thousand USD | -139.74% |
| 2019 | 1.47 Million USD | 49.59% |
| 2018 | 984 Thousand USD | 1074.26% |
| 2017 | -101 Thousand USD | 96.63% |
| 2016 | -2.99 Million USD | -74.96% |
| 2015 | -1.71 Million USD | -125.88% |
| 2014 | 6.61 Million USD | 330.58% |
| 2013 | 1.53 Million USD | -51.45% |
| 2012 | 3.16 Million USD | -47.9% |
| 2011 | 6.07 Million USD | -40.53% |
| 2010 | 10.21 Million USD | 26.85% |
| 2009 | 8.05 Million USD | -5.0% |
| 2008 | 8.47 Million USD | -11.06% |
| 2007 | 9.53 Million USD | 9.7% |
| 2006 | 8.69 Million USD | 9.67% |
| 2005 | 7.92 Million USD | 80.91% |
| 2004 | 4.38 Million USD | -42.86% |
| 2003 | 7.66 Million USD | 367.1% |
| 2002 | 1.64 Million USD | 135.21% |
| 2001 | -4.66 Million USD | 54.87% |
| 2000 | -10.32 Million USD | -1011.09% |
| 1999 | 1.13 Million USD | -53.01% |
| 1998 | 2.41 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -1.31 Million USD | -565.6% |
| 2024 Q2 | -1.82 Million USD | -38.61% |
| 2023 Q3 | -933 Thousand USD | -217.21% |
| 2023 FY | 2.28 Million USD | 131.89% |
| 2023 Q1 | 1.74 Million USD | 482.71% |
| 2023 Q4 | 282 Thousand USD | 130.23% |
| 2023 Q2 | 796 Thousand USD | -54.49% |
| 2022 Q4 | -457 Thousand USD | 89.39% |
| 2022 FY | -7.16 Million USD | -611.86% |
| 2022 Q3 | -4.3 Million USD | -356.14% |
| 2022 Q2 | -944 Thousand USD | 85.94% |
| 2022 Q1 | -6.71 Million USD | -495.06% |
| 2021 Q4 | 1.69 Million USD | 210.04% |
| 2021 Q1 | -239 Thousand USD | -108.67% |
| 2021 Q3 | 548 Thousand USD | 844.83% |
| 2021 Q2 | 58 Thousand USD | 124.27% |
| 2021 FY | 1.4 Million USD | 339.32% |
| 2020 Q3 | 182 Thousand USD | -67.27% |
| 2020 Q4 | 2.75 Million USD | 1414.29% |
| 2020 FY | -585 Thousand USD | -139.74% |
| 2020 Q1 | -3.27 Million USD | -968.17% |
| 2020 Q2 | 556 Thousand USD | 116.99% |
| 2019 FY | 1.47 Million USD | 49.59% |
| 2019 Q3 | -1.36 Million USD | -698.68% |
| 2019 Q4 | 377 Thousand USD | 127.62% |
| 2019 Q2 | 228 Thousand USD | 570.59% |
| 2019 Q1 | 34 Thousand USD | -98.05% |
| 2018 FY | 984 Thousand USD | 1074.26% |
| 2018 Q1 | -1.26 Million USD | -288.11% |
| 2018 Q3 | 890 Thousand USD | 332.98% |
| 2018 Q4 | 1.74 Million USD | 95.73% |
| 2018 Q2 | -382 Thousand USD | 69.83% |
| 2017 Q1 | -639 Thousand USD | 43.1% |
| 2017 FY | -101 Thousand USD | 96.63% |
| 2017 Q4 | 673 Thousand USD | 594.85% |
| 2017 Q3 | -136 Thousand USD | -13700.0% |
| 2017 Q2 | 1000.00 USD | 100.16% |
| 2016 Q3 | -813 Thousand USD | 3.21% |
| 2016 Q4 | -1.12 Million USD | -38.13% |
| 2016 Q1 | -221 Thousand USD | -295.58% |
| 2016 FY | -2.99 Million USD | -74.96% |
| 2016 Q2 | -840 Thousand USD | -280.09% |
| 2015 Q1 | -1.15 Million USD | -154.22% |
| 2015 Q3 | -775 Thousand USD | -882.83% |
| 2015 Q4 | 113 Thousand USD | 114.58% |
| 2015 FY | -1.71 Million USD | -125.88% |
| 2015 Q2 | 99 Thousand USD | 108.61% |
| 2014 Q1 | 1.33 Million USD | -62.1% |
| 2014 Q2 | 1.73 Million USD | 30.28% |
| 2014 FY | 6.61 Million USD | 330.58% |
| 2014 Q4 | 2.12 Million USD | 48.84% |
| 2014 Q3 | 1.42 Million USD | -18.01% |
| 2013 FY | 1.53 Million USD | -51.45% |
| 2013 Q4 | 3.52 Million USD | 433.97% |
| 2013 Q3 | -1.05 Million USD | -36.53% |
| 2013 Q2 | -772 Thousand USD | -388.61% |
| 2013 Q1 | -158 Thousand USD | -122.01% |
| 2012 Q3 | -79 Thousand USD | -106.08% |
| 2012 Q4 | 718 Thousand USD | 1008.86% |
| 2012 Q1 | 1.22 Million USD | -11.46% |
| 2012 FY | 3.16 Million USD | -47.9% |
| 2012 Q2 | 1.29 Million USD | 5.7% |
| 2011 Q3 | 220 Thousand USD | -91.27% |
| 2011 Q2 | 2.51 Million USD | 29.18% |
| 2011 Q1 | 1.95 Million USD | -33.4% |
| 2011 FY | 6.07 Million USD | -40.53% |
| 2011 Q4 | 1.38 Million USD | 530.91% |
| 2010 Q2 | 2.37 Million USD | -20.3% |
| 2010 Q4 | 2.92 Million USD | 50.69% |
| 2010 FY | 10.21 Million USD | 26.85% |
| 2010 Q3 | 1.94 Million USD | -18.09% |
| 2010 Q1 | 2.97 Million USD | 0.24% |
| 2009 Q2 | 805 Thousand USD | -65.76% |
| 2009 Q1 | 2.35 Million USD | -34.37% |
| 2009 FY | 8.05 Million USD | -5.0% |
| 2009 Q4 | 2.96 Million USD | 53.83% |
| 2009 Q3 | 1.93 Million USD | 139.75% |
| 2008 Q1 | 1.56 Million USD | -42.34% |
| 2008 Q4 | 3.58 Million USD | 92.89% |
| 2008 FY | 8.47 Million USD | -11.06% |
| 2008 Q3 | 1.85 Million USD | 25.98% |
| 2008 Q2 | 1.47 Million USD | -5.87% |
| 2007 Q2 | 2.55 Million USD | 12.95% |
| 2007 Q1 | 2.26 Million USD | -1.52% |
| 2007 Q3 | 2 Million USD | -21.72% |
| 2007 FY | 9.53 Million USD | 9.7% |
| 2007 Q4 | 2.71 Million USD | 35.8% |
| 2006 Q4 | 2.29 Million USD | 23.36% |
| 2006 Q2 | 2.29 Million USD | 2.19% |
| 2006 Q1 | 2.24 Million USD | -10.54% |
| 2006 FY | 8.69 Million USD | 9.67% |
| 2006 Q3 | 1.86 Million USD | -18.69% |
| 2005 Q1 | 506 Thousand USD | -73.78% |
| 2005 Q2 | -23.17 Million USD | -4680.43% |
| 2005 Q3 | 2.38 Million USD | 110.29% |
| 2005 Q4 | 2.5 Million USD | 5.08% |
| 2005 FY | 7.92 Million USD | 80.91% |
| 2004 Q3 | 1.67 Million USD | 176.44% |
| 2004 Q4 | 1.93 Million USD | 15.02% |
| 2004 Q2 | 607 Thousand USD | 272.39% |
| 2004 Q1 | 163 Thousand USD | -93.81% |
| 2004 FY | 4.38 Million USD | -42.86% |
| 2003 FY | 7.66 Million USD | 367.1% |
| 2003 Q2 | 2.11 Million USD | 73.55% |
| 2003 Q3 | 1.69 Million USD | -20.15% |
| 2003 Q4 | 2.63 Million USD | 55.56% |
| 2003 Q1 | 1.22 Million USD | 195.99% |
| 2002 Q2 | 1.48 Million USD | 25.63% |
| 2002 Q3 | 248 Thousand USD | -83.3% |
| 2002 Q1 | 1.18 Million USD | 897.98% |
| 2002 FY | 1.64 Million USD | 135.21% |
| 2002 Q4 | -1.27 Million USD | -612.92% |
| 2001 Q2 | -5.32 Million USD | -1127.22% |
| 2001 Q3 | 24 Thousand USD | 100.45% |
| 2001 FY | -4.66 Million USD | 54.87% |
| 2001 Q1 | 518 Thousand USD | 101.6% |
| 2001 Q4 | 118.43 Thousand USD | 393.5% |
| 2000 FY | -10.32 Million USD | -1011.09% |
| 2000 Q1 | 7.35 Million USD | 0.0% |
| 2000 Q4 | -32.39 Million USD | -540.37% |
| 2000 Q3 | 7.35 Million USD | 0.0% |
| 2000 Q2 | 7.35 Million USD | 0.0% |
| 1999 FY | 1.13 Million USD | -53.01% |
| 1998 FY | 2.41 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Akoya Biosciences, Inc. | -57.66 Million USD | 103.284% |
| AngioDynamics, Inc. | -97.71 Million USD | 101.938% |
| AtriCure, Inc. | -26.68 Million USD | 107.098% |
| Avinger, Inc. | -16.63 Million USD | 111.386% |
| Azenta, Inc. | -73.12 Million USD | 102.59% |
| BioLife Solutions, Inc. | -70.82 Million USD | 102.674% |
| The Cooper Companies, Inc. | 533.1 Million USD | 99.645% |
| Daxor Corporation | -177.07 Thousand USD | 1169.603% |
| Ekso Bionics Holdings, Inc. | -15.11 Million USD | 112.533% |
| Femasys Inc. | -14.5 Million USD | 113.054% |
| GlucoTrack, Inc. | -7.1 Million USD | 126.661% |
| Hologic, Inc. | 882.6 Million USD | 99.785% |
| ICU Medical, Inc. | 22.82 Million USD | 91.702% |
| Intuitive Surgical, Inc. | 1.76 Billion USD | 99.893% |
| KORU Medical Systems, Inc. | -10.26 Million USD | 118.442% |
| LeMaitre Vascular, Inc. | 37.08 Million USD | 94.892% |
| Innovative Eyewear, Inc. | -6.9 Million USD | 127.447% |
| Innovative Eyewear, Inc. | -6.9 Million USD | 127.447% |
| Masimo Corporation | 136.5 Million USD | 98.612% |
| Microbot Medical Inc. | -9.85 Million USD | 119.219% |
| Meihua International Medical Technologies Co., Ltd. | 14.67 Million USD | 87.094% |
| Merit Medical Systems, Inc. | 123.94 Million USD | 98.472% |
| Nephros, Inc. | -1.59 Million USD | 218.895% |
| NovoCure Limited | -232.87 Million USD | 100.813% |
| NEXGEL, Inc. | -3.47 Million USD | 154.472% |
| NEXGEL, Inc. | -3.47 Million USD | 154.472% |
| Singular Genomics Systems, Inc. | -102.8 Million USD | 101.842% |
| OraSure Technologies, Inc. | 54.07 Million USD | 96.498% |
| Pro-Dex, Inc. | 7.17 Million USD | 73.595% |
| Pulse Biosciences, Inc. | -43.57 Million USD | 104.347% |
| Predictive Oncology Inc. | -13.92 Million USD | 113.605% |
| Precision Optics Corporation, Inc. | -2.72 Million USD | 169.522% |
| QuidelOrtho Corporation | 139.1 Million USD | 98.638% |
| Repligen Corporation | 54.57 Million USD | 96.53% |
| Sanara MedTech Inc. | -4.21 Million USD | 144.933% |
| STAAR Surgical Company | 28.09 Million USD | 93.259% |
| Sharps Technology, Inc. | -10.12 Million USD | 118.703% |
| Utah Medical Products, Inc. | 16.77 Million USD | 88.711% |
| DENTSPLY SIRONA Inc. | -85 Million USD | 102.228% |
| Jin Medical International Ltd. | 2.86 Million USD | 33.944% |